Tepotinib + Ivonescimab (NCT07619339)

Name: Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339)
Uploaded: 2026-10-20T02:18:32.125Z
Duration: 1 min 3 s
Description: Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339). Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer. The researchers are doing this study to find out whether the combination of tepotinib and…

Cómo funciona tepotinib + ivonescimabNCT076193391 min

Tepotinib + Ivonescimab trial for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NCT07619339). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

Lo que dice el vídeo

Lee la transcripción

This trial is for adults with non-small cell lung cancer that has a MET exon 14 skipping change.

The idea: combine tepotinib, a daily pill that targets MET, with ivonescimab, an antibody given by vein every three weeks. The study tests up to two doses of tepotinib to find the best one with few or mild side effects.

This phase 1 study plans 16 patients. At Memorial Sloan Kettering Cancer Center in New York, Paul Paik leads it.

Public record; not medical advice.

Lee el resumen completo →

¿Ya estás en un ensayo?

Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.

Organizar mi ensayo

Prueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.

Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.